review
year
antivir
strategi
section
focu
discoveri
efficaci
antivir
drug
emerg
reemerg
singlestrand
posit
neg
strand
rna
virus
public
health
import
articl
pathogen
two
famili
posit
strand
rna
virus
flavivirus
coronavirus
three
famili
neg
strand
rna
famili
orthomyxovirus
filovirus
rhabdovirus
includ
vaccin
mani
virus
avail
vaccin
efficaci
moder
member
famili
constitut
major
clinic
need
effect
therapeut
drug
develop
effort
pathogen
differ
stage
desir
drug
profil
distinct
prior
global
outbreak
sever
respiratori
syndrom
coronaviru
sarscov
known
isol
human
coronavirus
caus
mild
upper
respiratori
diseas
recent
emerg
middl
east
respiratori
syndrom
coronaviru
merscov
suggest
addit
zoonot
coronavirus
continu
period
emerg
human
popul
futur
nucleotid
nucleosid
analogu
inhibitor
develop
use
mani
rna
virus
howev
uniqu
rnadepend
rna
proofread
activ
cov
exoribonucleas
respons
increas
resist
virus
nucleotid
nucleosid
analogu
inhibitor
pruijsser
denizen
describ
recent
develop
nucleotid
nucleosid
analogu
inhibitor
abil
inhibit
multipl
cov
multipl
efficaci
drug
target
activ
variou
hepat
c
viru
hcv
nonstructur
protein
success
develop
use
combin
treat
persist
hcv
infect
effect
greater
chanc
achiev
cure
luna
et
al
present
insid
overview
failur
success
period
year
led
success
develop
viabl
cell
cultur
model
hcv
discoveri
efficaci
antihcv
drug
success
stori
field
antivir
develop
provid
insight
may
applic
discoveri
antivir
addit
human
diseas
virus
futur
although
hcv
virus
zika
viru
west
nile
viru
dengu
viru
member
famili
flavivirida
belong
differ
taxonom
genera
hepaciviru
flaviviru
respect
differ
mani
characterist
includ
use
differ
host
protein
virion
attach
entri
differ
proteas
structur
affect
drug
target
lack
protein
member
genu
flaviviru
efficaci
antivir
drug
target
nonstructur
protein
member
genu
flaviviru
far
develop
zou
shi
review
strategi
use
discov
antivir
drug
zika
viru
differ
arthropodborn
flavivirus
caus
differ
diseas
target
popul
must
consid
develop
antivir
drug
need
antivir
drug
treat
zika
viru
infect
pregnant
women
prevent
congenit
defect
develop
fetu
significantli
limit
type
drug
use
two
articl
focu
treatment
influenza
infect
within
select
group
neg
strand
virus
influenza
virus
respons
highest
incid
rate
far
interpandem
year
caus
acut
respiratori
infect
highest
diseas
burden
elderli
major
effort
direct
develop
influenza
therapeut
last
year
first
new
inhibitor
class
nearli
two
decad
approv
human
use
although
standardofcar
drug
still
neuraminidas
inhibitor
articl
ohanlon
shaw
discuss
develop
possibl
clinic
impact
novel
influenza
viru
pa
endonucleas
inhibitor
baloxavir
marboxil
particular
emphasi
clinic
trial
data
prospect
emerg
viral
resist
inhibit
discuss
summar
approv
baloxavir
marboxil
redefin
prioriti
within
influenza
drug
develop
field
toward
proactiv
address
resist
problem
discoveri
stage
explor
combin
therapi
option
thu
recent
expand
therapeut
arsen
influenza
review
morgan
klein
util
influenza
exampl
summar
emerg
appreci
impact
biolog
sex
sociocultur
gender
norm
role
relat
exposur
infect
progress
diseas
access
accept
treatment
span
arc
anim
model
influenza
clinic
data
author
discuss
current
insight
correl
biolog
sex
immun
respons
influenza
viru
infect
efficaci
vaccin
antivir
drug
biolog
factor
juxtapos
evalu
effect
sociocultur
factor
administr
influenza
intervent
patient
complianc
compar
influenza
differ
clinic
threat
present
ebola
viru
infect
major
past
ebola
viru
outbreak
limit
geograph
size
case
fatal
rate
devastatingli
high
drug
develop
effort
filoviru
infect
receiv
major
boost
unusu
larg
outbreak
west
africa
result
casualti
spread
diseas
europ
north
america
overview
filoviru
replic
cycl
edward
basler
provid
succinct
overview
current
stage
experiment
filoviru
inhibitor
drug
candid
undergo
clinic
test
directact
hosttarget
antivir
candid
discuss
reflect
need
develop
broadspectrum
panfiloviru
inhibitor
rabi
neglect
diseas
term
drug
discoveri
sinc
preexposur
postexposur
prophylaxi
treatment
avail
howev
two
factor
identifi
articl
dupont
et
al
demonstr
complac
order
firstli
cost
logist
avail
restrict
limit
access
atrisk
popul
immunoglobulin
novel
drug
screen
technolog
isol
druggabl
target
identifi
develop
character
novel
antivir
candid
inhibitor
direct
influenza
viru
respiratori
syncyti
viru
measl
viru
discov
laboratori
differ
stage
experiment
formal
develop
compon
rabi
prophylaxi
build
case
valu
replac
suitabl
smallmolecul
drug
secondli
current
vaccin
crossprotect
newli
emerg
zoonot
lyssavirus
phylogroup
ii
follow
summari
past
antirabi
viru
drug
develop
effort
author
outlin
essenti
featur
viabl
drug
candid
provid
guidanc
earli
stage
drug
discoveri
effort
virus
examin
special
issu
exist
quasispeci
popul
rapid
develop
viral
resist
emerg
sever
case
major
threat
longterm
therapeut
success
expand
number
therapeut
approv
human
use
promis
drug
candid
preclin
clinic
develop
howev
novel
opportun
drug
combin
treatment
anticip
consid
valid
earli
develop
parallel
increas
appreci
impact
biolog
sociocultur
factor
treatment
efficaci
translat
develop
efficaci
model
clinic
trial
design
maxim
prospect
optim
treatment
option
inne
patient
popul
develop
